ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY24 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY24 earnings guidance on Friday. The company provided earnings per share guidance of $4.90-5.05 for the period, compared to the consensus earnings per share estimate of $4.72. The company issued revenue guidance of $594-602 million, compared to the consensus revenue estimate of $590.33 million. ANI Pharmaceuticals also updated its FY 2024 guidance to 4.900-5.050 EPS.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Raymond James boosted their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Wednesday, September 18th. Truist Financial upped their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. StockNews.com lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Piper Sandler assumed coverage on shares of ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $77.33.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock opened at $61.44 on Friday. The company has a market capitalization of $1.29 billion, a PE ratio of 52.51 and a beta of 0.71. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.07 and a current ratio of 3.97. The company has a 50-day simple moving average of $58.66 and a two-hundred day simple moving average of $61.52. ANI Pharmaceuticals has a one year low of $48.20 and a one year high of $70.81.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.